PreCardixBP®

Unlock the Power of Proprietary Bioactive Peptides for Cardiovascular Health.

PreCardixBP® is the world’s first clinically proven bioactive marine peptide designed to help maintain healthy blood pressure through natural ACE inhibition. Derived from the shells of Pandalus borealis shrimp, these small yet powerful peptides are highly bioactive and bioavailable, effectively inhibiting the ACE enzyme to support cardiovascular health. Backed by over a decade of research, PreCardixBP® has been clinically validated through trials that consistently demonstrate its effectiveness in lowering blood pressure. In fact, 89% of participants experienced meaningful reductions after just 8 weeks, with average decreases of 6.7 mmHg in systolic and 1.7 mmHg in diastolic pressure. Those with higher baseline readings saw even greater improvements, and results were noticeable within 2 to 8 weeks of daily use. Proven safe and effective, PreCardixBP® naturally inhibits ACE, a key regulator of blood pressure, without causing serious side effects such as hypotension. The optimal daily dose of 1200 mg has been established for clinically proven results. Regulatory approvals confirm its safety and efficacy across regions. In Canada, PreCardixBP® is approved as a Natural Health Product (NHP); in the United States, it is recognized as a New Dietary Ingredient (NDI); and in Europe, it is approved as a Novel Food. If you're an ingredient buyer looking to incorporate PreCardixBP® into your formulations, we’d love to discuss how our clinically proven marine peptides can enhance your products. Whether you're interested in tablets, capsules, or powder formulations, our team is ready to provide further details and explore how PreCardixBP® can support your cardiovascular health offerings. Contact us today to learn more and start the conversation.